NCT03232125 is a NA clinical trial of Ramosetron in Prostate Cancer, sponsored by Yonsei University.

Who is sponsoring NCT03232125?

NCT03232125 is sponsored by Yonsei University.

What drugs are being tested in NCT03232125?

Interventions in NCT03232125: Ramosetron, Normal saline.

What condition does NCT03232125 study?

NCT03232125 studies Prostate Cancer.

Is NCT03232125 still recruiting?

NCT03232125 is currently completed. Last updated 25 August 2020.

Last reviewed 2020-08-25 · How we verify

NCT03232125

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of Ramosetron on Heart Rate-corrected QT Interval During Robot-assisted Laparoscopic Prostatectomy With Steep Trendelenburg Position

Completed NA Last updated 25 August 2020

What this trial tests

NA trial testing Ramosetron in Prostate Cancer in 54 participants. Completed in 12 June 2020.

Timeline

1 August 2017

Primary endpoint
9 June 2020

12 June 2020

Quick facts

Lead sponsor	Yonsei University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	prevention
Enrollment	54
Start date	1 August 2017
Primary completion	9 June 2020
Estimated completion	12 June 2020
Sites	1 location across South Korea

Drugs / interventions tested

Ramosetron — full drug profile →
Normal saline

Conditions studied

Prostate Cancer — all drugs for Prostate Cancer →

Sponsor

Yonsei University

Who can join

Adults 20 to 80, any sex, with Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Intraperitoneal insufflation of carbon dioxide may affect the sympathetic activity that leads to changes in ventricular re-polarization. This in turn can result in changes of heart rate-corrected QT (QTc) interval. Ramosetron is a 5-hydroxytryptamine three receptor antagonist and widely used anti-emetics. However, QTc interval prolongation has been observed in a number of patients after administration of 5-HT3 receptor antagonists. The aim of this study is to evaluate the effects of ramosetron on QTc interval and possible cardiovascular adverse effects during robot-assisted laparoscopic prostatectomy with steep Trendelenburg position.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Heart-Rate-Corrected QT Interval Response to Ramosetron during Robot-Assisted Laparoscopic Prostatectomy: A Randomized Trial.
Lee B, Kim SY, Kim SH, Yang H, et al · · 2022 · PMID 35629233 · DOI 10.3390/jpm12050811

Verify or expand the search:

Other trials of Ramosetron

Trials testing the same drug.

NCT06166615 — The Safety and Efficacy of 5-HT3 Receptor Antagonist (Ramosetron) for the Treatment of Fecal Incontinence · Phase 2, PHASE3 · unknown
NCT04297293 — Ramosetron OD Tablet and Postdischarge Nausea and Vomiting · Phase 4 · unknown
NCT03278522 — Ramosetron Pre-treatment for PONV and QT Prolongation · Phase 4 · completed
NCT02612649 — Special Drug Use Surveillance of Irribow in Female Patients · completed
NCT03017222 — Therapeutic Efficacy of Ramosetron for Treatment of Established PONV After Laparoscopic Surgery · NA · completed

Other recruiting trials for Prostate Cancer

Currently open trials in the same condition.

NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting

Other Yonsei University trials

Trials by the same sponsor.

NCT07547592 — Gemcitabine and Docetaxel With or Without Bevacizumab (Onbevzi) for Soft Tissue Sarcoma · Phase 2 · not yet recruiting
NCT07524101 — Moderate-Intensity Statin Plus Ezetimibe in CKD and ASCVD · NA · not yet recruiting
NCT07506629 — Adductor Canal Block Methods in Bilateral Total Knee Arthroplasty · NA · not yet recruiting
NCT07515716 — Effects of High Flow Humidified Oxygen on Umbilical Artery Acid-base Balance in Cesarean Section Under Spinal Anesthesia · NA · not yet recruiting
NCT07507188 — Collaborative Clinical-translational Cohort of Amivantamab Plus Lazertinib and Amivantamab Plus Chemotherapy in Patients · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03232125 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Yonsei University
Last refreshed: 25 August 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03232125.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing